Meda has full subscription on €214m rights issue
Meda, the Swedish pharmaceuticals firm listed in Stockholm, has successfully completed a Skr2.027bn (€214m) rights issue for 10% of its existing share capital. It had a 99.7% take-up rate, with heavy oversubscriptions.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: